Dr Michael Hill
Laboratory Scientific Director
- MRC PHRU Director of Laboratories
Dr Hill joined CTSU in 2009 and is the Laboratory Scientific Director of the NDPH Wolfson Laboratories. He has a background in population-based studies and functional studies associated with respiratory and cardiovascular disease. He manages a team of 40 research and technical staff and is responsible for senior strategic oversight of all aspects of laboratory research within NDPH.
Dr Hill works closely with NDPH’s principal investigators, providing central laboratory support for their clinical trials and observational studies ensuring the scientific integrity of the laboratory work.
Research interests include investigating new biochemical markers and validating analytical methods suitable for large-scale research. NDPH Wolfson Laboratories are a UKAS accredited testing laboratory (ISO 17025:2005; No. 2799) with extensive computer automation and a particular expertise in developing reliable high-throughput methods of analysis in clinical chemistry and protein biomarkers.
Previous history: Dr Hill gained his DPhil at the University of Oxford in 1992 and continued his post-doctoral studies at the Nuffield Department of Clinical Medicine, Oxford and The Wellcome Trust Centre for Human Genetics, Oxford. In 1998, he joined the Division of Medicine at University College London where he led a research group.
CETP gene variants and risk of vascular and non-vascular diseases in ~150,000 Chinese adults
Millwood IY. et al, (2017), JAMA Cardiology
Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study.
Allen RJ. et al, (2017), Lancet Respir Med, 5, 869 - 880
Effects of Vitamin D on Blood Pressure, Arterial Stiffness, and Cardiac Function in Older People After 1 Year: BEST-D (Biochemical Efficacy and Safety Trial of Vitamin D).
Tomson J. et al, (2017), J Am Heart Assoc, 6
Diabetes and premature mortality in Mexico City: Blood-based prospective study of 15,000 Mexican adults with 12 years’ mortality follow-up
Herrington W. et al, (2017), None
Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care.
Hin H. et al, (2016), Osteoporos Int